Pharmacokinetically modified human serum albumin based therapeutic design and development

Kazuaki Taguchi, Victor Tuan Giam Chuang, Keishi Yamasaki, Masaki Otagiri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Human serum albumin (HSA) is synthesized predominantly in the liver, and has an extraordinarily long circulatory half-life (~19 days). Since HSA is responsible for 80% of the colloidal osmotic pressure of plasma, the patients with hypoalbuminemia are typically given a plasma expander to increase the plasma volume. Clinically, using HSA as an extender is preferable to other options, such as dextran, hydroxylethyl starch, due to its long retention in plasma. However, the circulatory half-life of HSA is significantly- impacted by structural changes of HSA and pathological conditions. Recent scientific advances have revealed new information regarding the factors that influence the pharmacokinetic properties of HSA. In this chapter, we provide an overview of the impact of HSA structure and biotransformation upon the pharmacokinetic properties of HSA, and discuss new possibilities for the therapeutic potential of HSA based on its pharmacokinetic properties.

Original languageEnglish
Title of host publicationHuman Serum Albumin (HSA)
Subtitle of host publicationFunctional Structure, Synthesis and Therapeutic Uses
PublisherNova Science Publishers, Inc.
Pages69-89
Number of pages21
ISBN (Electronic)9781634830157
ISBN (Print)9781634829632
Publication statusPublished - 2015 Jul 1
Externally publishedYes

Fingerprint

Serum Albumin
Pharmacokinetics
Plasmas
Therapeutics
Half-Life
Hypoalbuminemia
Plasma Volume
Osmotic Pressure
Biotransformation
Dextrans
Starch
Liver

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Taguchi, K., Chuang, V. T. G., Yamasaki, K., & Otagiri, M. (2015). Pharmacokinetically modified human serum albumin based therapeutic design and development. In Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses (pp. 69-89). Nova Science Publishers, Inc..

Pharmacokinetically modified human serum albumin based therapeutic design and development. / Taguchi, Kazuaki; Chuang, Victor Tuan Giam; Yamasaki, Keishi; Otagiri, Masaki.

Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses. Nova Science Publishers, Inc., 2015. p. 69-89.

Research output: Chapter in Book/Report/Conference proceedingChapter

Taguchi, K, Chuang, VTG, Yamasaki, K & Otagiri, M 2015, Pharmacokinetically modified human serum albumin based therapeutic design and development. in Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses. Nova Science Publishers, Inc., pp. 69-89.
Taguchi K, Chuang VTG, Yamasaki K, Otagiri M. Pharmacokinetically modified human serum albumin based therapeutic design and development. In Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses. Nova Science Publishers, Inc. 2015. p. 69-89
Taguchi, Kazuaki ; Chuang, Victor Tuan Giam ; Yamasaki, Keishi ; Otagiri, Masaki. / Pharmacokinetically modified human serum albumin based therapeutic design and development. Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses. Nova Science Publishers, Inc., 2015. pp. 69-89
@inbook{6a93e1fe2a4c48e5bff1228580243926,
title = "Pharmacokinetically modified human serum albumin based therapeutic design and development",
abstract = "Human serum albumin (HSA) is synthesized predominantly in the liver, and has an extraordinarily long circulatory half-life (~19 days). Since HSA is responsible for 80{\%} of the colloidal osmotic pressure of plasma, the patients with hypoalbuminemia are typically given a plasma expander to increase the plasma volume. Clinically, using HSA as an extender is preferable to other options, such as dextran, hydroxylethyl starch, due to its long retention in plasma. However, the circulatory half-life of HSA is significantly- impacted by structural changes of HSA and pathological conditions. Recent scientific advances have revealed new information regarding the factors that influence the pharmacokinetic properties of HSA. In this chapter, we provide an overview of the impact of HSA structure and biotransformation upon the pharmacokinetic properties of HSA, and discuss new possibilities for the therapeutic potential of HSA based on its pharmacokinetic properties.",
author = "Kazuaki Taguchi and Chuang, {Victor Tuan Giam} and Keishi Yamasaki and Masaki Otagiri",
year = "2015",
month = "7",
day = "1",
language = "English",
isbn = "9781634829632",
pages = "69--89",
booktitle = "Human Serum Albumin (HSA)",
publisher = "Nova Science Publishers, Inc.",
address = "United States",

}

TY - CHAP

T1 - Pharmacokinetically modified human serum albumin based therapeutic design and development

AU - Taguchi, Kazuaki

AU - Chuang, Victor Tuan Giam

AU - Yamasaki, Keishi

AU - Otagiri, Masaki

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Human serum albumin (HSA) is synthesized predominantly in the liver, and has an extraordinarily long circulatory half-life (~19 days). Since HSA is responsible for 80% of the colloidal osmotic pressure of plasma, the patients with hypoalbuminemia are typically given a plasma expander to increase the plasma volume. Clinically, using HSA as an extender is preferable to other options, such as dextran, hydroxylethyl starch, due to its long retention in plasma. However, the circulatory half-life of HSA is significantly- impacted by structural changes of HSA and pathological conditions. Recent scientific advances have revealed new information regarding the factors that influence the pharmacokinetic properties of HSA. In this chapter, we provide an overview of the impact of HSA structure and biotransformation upon the pharmacokinetic properties of HSA, and discuss new possibilities for the therapeutic potential of HSA based on its pharmacokinetic properties.

AB - Human serum albumin (HSA) is synthesized predominantly in the liver, and has an extraordinarily long circulatory half-life (~19 days). Since HSA is responsible for 80% of the colloidal osmotic pressure of plasma, the patients with hypoalbuminemia are typically given a plasma expander to increase the plasma volume. Clinically, using HSA as an extender is preferable to other options, such as dextran, hydroxylethyl starch, due to its long retention in plasma. However, the circulatory half-life of HSA is significantly- impacted by structural changes of HSA and pathological conditions. Recent scientific advances have revealed new information regarding the factors that influence the pharmacokinetic properties of HSA. In this chapter, we provide an overview of the impact of HSA structure and biotransformation upon the pharmacokinetic properties of HSA, and discuss new possibilities for the therapeutic potential of HSA based on its pharmacokinetic properties.

UR - http://www.scopus.com/inward/record.url?scp=84957035515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957035515&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84957035515

SN - 9781634829632

SP - 69

EP - 89

BT - Human Serum Albumin (HSA)

PB - Nova Science Publishers, Inc.

ER -